Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - PhaseBio Pharmaceuticals Inc | ex-322xphas10xk2020.htm |
| EX-31.2 - EX-31.2 - PhaseBio Pharmaceuticals Inc | ex312-phas10xk2020.htm |
| EX-31.1 - EX-31.1 - PhaseBio Pharmaceuticals Inc | ex311-phas10xk2020.htm |
| EX-23.1 - EX-23.1 - PhaseBio Pharmaceuticals Inc | ex231-10xk2020.htm |
| EX-10.3 - EX-10.3 - PhaseBio Pharmaceuticals Inc | ex103-phas10xk2020.htm |
| 10-K - 10-K - PhaseBio Pharmaceuticals Inc | phas-20201231.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of PhaseBio Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
(1)The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
| Date: March 15, 2021 | By: | /s/ Jonathan P. Mow | |||||||||
| Jonathan P. Mow Chief Executive Officer | |||||||||||
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.